SB 415286Cat. No. 1617 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: 3-[(3-Chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione |
Biological Activity
Potent and selective glycogen synthase kinase-3 (GSK-3) inhibitor (Ki = 31 nM for GSK-3α); competes with ATP. Has minimal activity against 24 other protein kinases (IC50 > 10 μ M). Stimulates glycogen synthesis, gene transcription and is neuroprotective.Licensing Information
Sold for research purposes under agreement from GlaxoSmithKlineCertificate of Analysis / Safety Data Sheet
References
Coghlan et al (2000) Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem.Biol. 7 793. PMID: 11033082.
Cross et al (2001) Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J.Neurochem. 77 94. PMID: 11279265.
Liang and Chuang (2006) Regulation and function of glycogen synthase kinase-3 isoforms in neuronal survival. J.Biol.Chem. 282 3904. PMID: 17148450.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: SB 415286, supplier, Potent, selective, GSK-3, inhibitors, Glycogen, Synthase, Kinases, 3, Carbohydrate, Metabolism, SB415286, GlaxoSmithKline, GSK
Quick Order
Find multiple products by catalog number
New Products in this Area
Potent inhibitor of Abl T315l mutant and wild-type Abl kinases
Flavopiridol hydrochlorideCyclin-dependent kinase inhibitor
GSK2578215APotent, selective LRRK2 inhibitor; brain penetrant
AmlexanoxInhibitor of TBK1 and IKKε; antiallergic agent
PF 05212384Potent and selective dual PI 3-kinase/mTOR inhibitor
PF 03814735Aurora kinase A and B inhibitor
PF 04691502Dual PI 3-K/mTOR inhibitor
TNPInhibitor of IP6K; also inhibits IP3K
ACHPSelective IKKα and IKKβ inhibitor
PD 0332991 isethionatePotent, selective Cdk4/6 inhibitor; brain penetrant
CZC 24832Selective inhibitor of PI 3-Kinase γ
LY 333531 hydrochlorideProtein kinase C inhibitor; selective for β isozymes
PF 06465469Potent inhibitor of interleukin-2 inducible T cell kinase (ITK). Also inhibits BTK
10Z-HymenialdisinePan kinase inhibitor; potently inhibits MEK-1
CP 690550 citratePotent JAK inhibitor
WYE 687 dihydrochloridePotent and selective mTOR inhibitor
N,N-DimethylsphingosineSphingosine kinase inhibitor
PEP 005Protein kinase C activator
CZC 54252 hydrochloridePotent LRRK2 inhibitor; neuroprotective
Bisindolylmaleimide IIPotent PKC inhibitor and nicotinic receptor antagonist
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.






